PCO-Syndrom.de - Ihre PCOS-Ansprechpartner in Deutschland

Standard-Literatur zum Thema PCOS


  1. Achad C, Thiers J (1921) Le virilisme pilaire et son association a l´insuffisance glycolytique (diabete des femmes a barbe). Bull Acad Natl Med 86: 51-64.

  2. Albareda M, Rodriguez-Espinosa J, Murungo M, de Leiva A, Corcoy R (2000) Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 43:1507-1511.

  3. Arslanian SA, Lewy VD, Danadian K (2001) Glucose Intolerance in Obese Adolescents with Polycystic Ovary Syndrome: Roles of Insulin Resistance and ß-Cell Dysfunction and Risk of Cardiovascular Disease*. J Clin Endocrinol Metab 86: 66-71.

  4. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF (2000) A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasians Women from Spain. J Clin Endocrinol Metab 85:2434-2438.

  5. Auwerx J (1999) Review. PPARy2, the ultimate thrifty gene. Diabetologia 42: 1033-1049.

  6. Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR (1998) Association of the Pro 12Ala Variant in the Peroxisome Proliferator-Activated Receptor-y2 Gene With Obesity in Two Caucasian Populations. Diabetes 47: 1806-1808.

  7. Brähler E, Scheer JW (1979) Skalierung psychosomatischer Beschwerdekomplexe mit dem Gießener Beschwerdebogen (GBB). Psychother med Psychol 29: 14-27.

  8. Brown J, Winkelmann RK (1968) Acanthosis nigricans: a study of 90 cases. Medicine 47: 33-51.

  9. Burghen GA, Givens JR, Kitabchi AE (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50: 113-116.

  10. Chang RJ, Nakamura RM, Judd HL, Kaplan SA (1983) Insulin Resistance in Nonobese Patients with Polycystic Ovarien Disease. J Clin Endocrinol Metab 57: 356-359.

  11. Chen C (1998) Troglitazone: an antidiabetic agent. Am J Health Syst Pharm 55(9): 905-925.

  12. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.

  13. Coetzee EJ, Jackson WPU (1979) Metformin in management of pregnant insulin-indipendent diabetics. Diabetologia 16: 241-245.

  14. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A (1998) Development of a health-related quality-of-life questionnaire (PCOQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 83(6): 1976-1987.

  15. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J (1998) A Pro 12Ala substitution in PPARy2 association with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genetics 20: 284-287.

  16. Denno KM, Sadler TW (1994) Effects of Biguanide Class of Oral Hypoglycemic Agents on Mouse Embryogenesis. Teratology 49: 260-266.

  17. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A (1998) Therapeutic effects of metformin on insulin resistence and hyperandrogenism in polycystic ovary syndrome. European J of Endocrinol 138: 269-274.

  18. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound Peripheral Insulin Resistance, indipendent of Obesity, in Polycystic Ovary Syndrome. Diabetes 38: 1165-1174.

  19. Dunaif A , Finegood DT (1996) ß-Cell Dysfunktion Independent of Obesity and Glucose Intolerance in the Polycystic Ovary Syndrome. J of Clin Endocrinol Metab 81: 942-947.

  20. Dunaif A (1997) Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocrine Reviews 18: 774-800.

  21. Dunaif A, Thomas A (2001) Current Concepts in the Polycystic Ovary Syndrome. Ann. Rev. Med. 52: 401-19

  22. Eagelson CA, Gingrich MB, Pastor CL, Arora TA, Burt CM, Evans WS, Marshall JC (2000) Polycystic Ovarian Syndrome: Evidence that Flutamide Restores Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Estradiol and Progesterone. J Clin Endocrinol Metab 85: 4047-4052)

  23. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS (1997) Effects of Metformin on Insulin Secretion, Insulin Action and Ovarian Steroidgenesis in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 82: 524-530)

  24. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS (1997) Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidgenesis, and fibrinolysis in women with polycystic ovary syndrome*. J Clin Endocrinol Metab 82: 2108-2116.

  25. Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, Garcia-Robles R (2000) High Prevalence of the Polycystic Ovary Syndrome and Hirsutism in Women with Type 1 Diabetes mellitus. J Clin Endocrinol Metab 85: 4182-4187.

  26. Evans D, de Heer J, Hagemann C., Wendt D, Wolf A, Beisiegel U, Mann WA (2001) Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor y (PPARy) gene and type 2 diabetes. Exp Clin Endocrinol Diabetes 109: 151-154.

  27. Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol 21: 1440-1447.

  28. Franke HG (1992) Eine weitere Überprüfung der Symptom-Check-Liste (SCL-90) als Forschungsinstrument. Diagnostica 38: 160-167.

  29. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002 Jun; 16(2): 263-272.

  30. Franks S (1995) Polycystic Ovary Syndrome. N Engl J Med 333: 853-861.

  31. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, Mc Carthy M ( 1998) Genetics of polycystic ovary syndrome. Molecular and Cellular Endocrinol 145: 123-128.

  32. Franks S, Gharani N, Gilling-Smith C (1999) Polycystic ovary syndrome: evidence for a primary disorder of ovarian steroidogenesis. J Steroid Biochem Mol Biol 69: 269-272.

  33. Gharani N et al. (1997) Association of the steroid synthesis gene CYP 11a with polycystic ovary syndrome and hyperandrogenism. Human Molecular Genetics 6: 397-402.

  34. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod. 2003 Aug;18(8):1618-25.

  35. Govind A, Obhrai MS, Clayton RN (1999) Polycystic Ovaries Are Inherited as an Autosomal Dominant Trait: Analysis of 29 Polycystic Ovary Syndrome and 10 Control Families. J Clin Endocrinol Metab 84: 38-43.

  36. Guleki B, Turhan NO, Senoz S, Kukner S, Oral H, Gokmen O (1993) Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. Gynecol Endocrinol 7(4).273-277.

  37. Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003 Jul;18(7):1438-41.

  38. Haffner SM, Miettinen H, Stern MP (1997) The Homeostasis Model in the San Antonio Heart Study. Diabetes Care 20(7): 1087-1100.

  39. Hahlweg K (1979) Konstruktion und Validierung des Partnerschaftsfragebogens PFB. Zeitschrift für Klinische Psychologie 8: 17-40.

  40. Hague WM, Adams J, Algar V, Drummond V, Schwarz G, Bottazzo GF, Jacobs HS (1990) HLA Association in patients with Polycystic Ovaries and patients with congenital Adrenal Hyperplasia caused by 21-Hydroxylase Deficiency. Clin Endocrinol 32: 407-415.

  41. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K (1999) Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome. Fertil Steril 71(2): 323-327.

  42. Heider U, Pedal I, Spanel-Borowski K (2001) Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries. Fertil Steril 75 : 1141-1147.

  43. Heinonen S, Korhonen S, Hippeläinen M, Hiltunen M, Mannermaa A, Saarikoski S (2001) Apolipoprotein E alleles in women with polycystic ovary syndrome. Fertil Steril 75: 878-880.

  44. Hermans MP, Levy JC, Morris RJ, Turner RC (1999) Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42: 678-687.

  45. Holmang A, Larsson BM, Brzezinska Z, Bjorntorp P (1992) Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 262: E851-E855.

  46. Janssen OE, Öffner A, Schopohl J, Brabant G. Das metabolische Syndrom bei polyzystischen Ovarien: Ätiologie, Diagnose und Therapie im Überblick. Klinikarzt 2000 Jul;6(29):163-166. Review

  47. Kahn SE, Prigeon RL, Mc Cullogh DK (1993) Quantification of the relationship between insulin sensitivity and ß-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672.

  48. Kashar-Miller M, Azziz R (1999) Heritability and the risk of developing androgen excess. J Steroid Biochem Mol Biol 69: 261-268.

  49. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. J Clin Endocrinol Metab 85: 2402-2410.

  50. Kerekjarto v. M, Meyer AE, Zerssen v D (1972) Die HHM-Beschwerdeliste bei Patienten einer internistischen Ambulanz. Z Psychosom Med Psychoanal 18: 1-16.

  51. Kimura I, M.D, Togashi K, M.D, Kawakami S,M.D, Nakano Y,M.D, Takakura K,M.D, Mori T,M.D, Konishi J,M.D (1996) Polycystic Ovaries: Implications of Diagnosis with MR Imaging. Radiology 201: 549-552.

  52. Knochenhauer ES, Key TJ, Kashar-Miller M, Waggoner W, Boots LR, Azziz R (1998) Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States : A Prospective Study. J Clin Endocrinol Metab 83:3078-3082.

  53. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, Häring HU (1999) The PPARy2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42: 758-762.

  54. Kovacs GT .Polycystic Ovary Syndrome. Cambridge University Press.

  55. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P (2000) Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet 356: 1166-1167.

  56. Legro RS, Driscolli D, Strauss JF, Fox J, Dunaif A (1998) Evidence for genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95: 14956-14960.

  57. Legro RS et al. (1998) Phenotype to Genotype in Polycystic Ovary Syndrome.Rec Progress Horm Res 53: 217-256.

  58. Legro RS, Kunselmann AR, Dodson WC, Dunaif A (1999) Prevalance and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women) J Clin Endocrinol Metab 84: 165-169.

  59. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003 Jun;24(3):302-12

  60. Matthews D et al.(1985) Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412-419.

  61. Mitchell DG,M.D et al. (1986) Polycystic Ovaries: MR Imaging. Radiology 160: 425-429.

  62. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M (2000) Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles , and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double- Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation. J Clin Endocrinol Metab 85: 139-146.

  63. Moran C, Huerta R, Conway-Myers BA, Hines GA, Azziz R (2001) Altered autophosphorylation of the insulin receptor in the ovary of a woman with polycystic ovary syndrome. Fertil Steril 75(3): 625-628.

  64. Morin-Papunen LC, Koivunen RM, Tomas C, Ruokonen A, Martikainen HK (1998) Decreased Serum Leptin Concentrations during Metformin Therapy in Obese Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 83: 2566-2568.

  65. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.J Clin Endocrinol Metab 2003 Jan;88(1):148-56

  66. Nagamani M , M.D., Van Dinh T, M.D., Kelver ME, M.D. (1986) Hyperinsulinemia in hyperthecosis of the ovaries.

  67. Nestler JE, M.D, Jakubowicz, M.D (1996) Decrease in ovarien cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335: 617-623.

  68. Nestler JE, M.D,Jakubowicz DJ, M.D, Evans WS, M.D, Pasquali R, M.D (1998) Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. N Engl J Med 338: 1876-1880.

  69. Ovalle F., Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002 Jun; 77(6): 1095-1105.

  70. Padmanabhan V, Christman GM, Randolph JF, Kelch RP, Marshall JC, Beitins IZ (2001) Dynamics of bioactive follicle-stimulation hormone secretion in women with polycystic ovary syndrome: effects of estradiol and progesterone. Fertil Steril 75: 881-888.

  71. Paoletti AM, Cagnacci A, Depau GF, Orru M, Ajossa S, Melis GB (1996) The chronic administration of cabergolin normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome.

  72. Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G, Johnson A, Cronin J, Steinberg HO, Baron AD (1999) Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 22(8): 1310-1317.

  73. Pasquali R, Casimirri F, Venturoli S, Antonio M, Morselli L, Reho S, Pezzoli A, Paradisi R (1994) Body Fat Distribution Has Weight-Indipendent Effects on Clinical, Hormonal, and Metabolic Features of Women With Polycystic Ovary Syndrome.

  74. Pasquali R et al. (2000) Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without Polycystic Ovary Syndrome. J Clin Endocrinol Metab 85: 2767-2774.

  75. Piacquadio K, Hollingsworth DR, Murphy H (1991) Effects of in-utero exposure to oral hypoglycemic drugs. Lancet 338: 81-122.

  76. Pierpoint T, Mc Keigue PM, Isaacs AJ, Wild SH, Jacobs HS (1998) Mortality of Women with Polycystic Ovary Syndrome at Long term Follow-up. J Clin Epidemiol 51: 581-586.

  77. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC (1999) The Insulin-Related Ovarian Regulatory System in Health and Disease. Endocrine Reviews 20(4): 535-582.

  78. Radziuk J (2000) Clinical Review 119. Insulin Sensitivity and Its Measurement: Structural Commonalities among the Methods*. J Clin Endocrinol Metab 85: 4426-4433.

  79. Reaven GM (1988) Role of Insulin Resistance in Human Disease. Diabetes 37: 1595-1607.

  80. Richards JA S (2001) Perspective: The Ovarien Follicle- A Perspective in 2001. Endocrinology 142: 2184-2193.

  81. Rief W, Schäfer S, Fichter MM (1992) SOMS: Ein Screening-Verfahren zur Identifizierung von Personen mit somatoformen Störungen. Diagnostica 38: 228-241.

  82. Rincon J, Holmang A, Wahlstrom EO, Lonnroth P, Bjorntorp P, Zierath JR, Wallberg-Henriksson H (1996) Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes 45: 615-621.

  83. Sattar N, Hopkinson ZE, Greer IA (1998) Insulin-sensitising agents in polycystic-ovary syndrome. Lancet 31: 305-307.

  84. Sir-Petermann T. et al., Prevalence of type 2 diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia 2002 Jun; 45(7): 959-964.

  85. Spiegelmann BM (1998) PPARy2: Adipogenic Regulator and Thiazolidinedione Receptor. Diabetes 47: 507-514.

  86. Steyer R, Schwenkmezger P, Notz P, Eid M (1994) Testtheoretische Analysen des Mehrdimensionalen Befindlichkeitsfragebogens (MDBF). Diagnostica 40: 320-328.

  87. Taylor AE (1998) Polycystic ovary syndrome. Endocrinol Metab Clin Noth Am 27(4): 877-902,ix.

  88. Taylor SI, Accili D, Imai Y (1994) Insulin resistance or insulin deficiency. Wich is the primary cause of NIDDM. Diabetes 43:735-740.

  89. Tucci S, Futterweit W, Conception ES, Greenberg DA, Villanueva R, Davies TF, Tomer Y (2001) Evidence for Association of Polycystic Ovary Syndrome in Caucasian Women with a Marker at the Insulin Receptor Gene Locus. J Clin Endocrinol Metab 86: 446-449

  90. Urbanek et al. (1999) Thirty-seven candidate genes for polycystic ovary syndrome: Strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 96: 8573-8578.

  91. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinemia, Insulin Resistence, Hyperandrogenemia, and Systolic Blood Pressure, while Facilitating Normal Menses and Pregnancy. Metabolism 43: 647-654.

  92. Velazquez EM, M.D, Acosta A, M.D., Mendoza SG, M.D (1997) Menstrual Cyclicity After Metrormin Therapy in Polycystic Ovary Syndrome. Obstet Gynecol 90: 392-395.

  93. Velazquez EM, Mendoza S, Wang P, Glueck CJ (1997) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a) , and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46(4): 454-457.

  94. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP (2001) Polycystic Ovary Syndrome Is Associated with Obstructive Sleep Apnea and Daytime Sleepiness: Role of Insulin Resistance*. J Clin Endocrinol Metab 86: 517-520.

  95. Vicennati V, Gambineri A, Calzoni F, Casimirri F, Macor C, Vettor R, Pasquali R (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism 47(8):988-992.

  96. Vigoroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magre J (1998) Brief Genetics Report. Human Peroxisome Proliferator-Activated Receptor y2. Diabetes 47: 490-492.

  97. Vbrikova J, Hill M, Starka L, Vondra K, Sulcova J, Snajderova M, Cibula D, Pobisova Z (2000) An analysis of the relationship between insulin resistance and the activity of steroid C 17,20-lyase and 3ß-hydroxysteroid dehydrogenase in ovaries and adrenals in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 108: 455-462.

  98. Vbrikova J, Hill M, Starka L, Cibula D, Bendlova B, Vondra K, Sulcova J, Snajderova M (2001) The effects of long term metformin treatment on adrenal And ovarian steroidogenesis in women with polycystic ovary syndrome. Eur J Endocrinol 144:619-628.

  99. Waterworth et al. (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 349: 986-990.

  100. Wild S, Pierpoint T, Mc Keigue P, Jacobs H (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 52: 595-600.

  101. Wu XK, Zhou SY, Sallinen K, Pöllänen P, Erkkola R (2000) Ovarian-adrenal cross-talk in polycystic ovary syndrome: evidence from wedge resection. European J Endocrinol 143: 383-388.

  102. Zawalich WS, Kelley GG (1995) The pathogenesis of NIDDM: the role of the pancreatic beta-cell. Diabetologia 38: 986-991.